GLP-1 Misuse in Eating Disorders: Clinical Recognition

The Intersection of GLP-1 Agonists and Eating Disorder Pathology

Recent clinical observations reveal a concerning pattern: patients with active or remitted eating disorders are misusing GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) as appetite suppressants, often without medical oversight. This represents a significant deviation from the FDA-approved indication and demands provider awareness.

Why GLP-1s Are Vulnerable to Misuse in This Population

GLP-1 agonists work via multiple mechanisms that directly target eating disorder psychopathology:

Appetite suppression through GCG-R signaling. GLP-1 receptors in the hypothalamus and brainstem suppress orexigenic (appetite-stimulating) neurons while potentiating satiety signals. This creates profound food aversion—precisely what eating disorder patients seek to reinforce restrictive behavior.

Delayed gastric emptying. At therapeutic doses, these compounds slow stomach-to-intestine transit, creating prolonged fullness and bloating sensations. Patients with anorexia nervosa often interpret this as "proof" restriction is working at a physiological level.

Visceral reward suppression. GLP-1 signaling reduces the hedonic value of food via mesolimbic dopamine pathways. Food loses its reward signal—a reinforcement mechanism in eating disorders.

Unlike older appetite suppressants (phentermine, topiramate), GLP-1 agonists carry pharmaceutical legitimacy and physician endorsement for weight loss, creating a veneer of safety that enables rationalization of misuse.

Clinical Red Flags: What to Screen For

When evaluating patients requesting GLP-1s, clinicians should assess:

• History of eating disorder diagnosis (anorexia nervosa, bulimia nervosa, restrictive eating patterns)
• Rapid weight loss escalation despite reported caloric intake
• Obsessive food tracking or ritualization beyond diabetes management
• Body composition obsession with emphasis on muscle loss rather than fat loss
• Delayed presentation of metabolic complications (hypokalemia, hypophosphatemia, hypomagnesemia despite apparent "stable" weight)
• Dismissal of hunger cues or pride in appetite suppression
• Secretive medication use or dose escalation beyond prescribed amounts

The Biochemical Danger: Metabolic Refeeding Syndrome Risk

Eating disorder patients using GLP-1s face compounded refeeding syndrome risk. GLP-1 agonists themselves cause electrolyte depletion (particularly phosphate, potassium, magnesium) through altered renal handling and GI secretion. Combined with caloric restriction, this creates a perfect storm:

• Depleted intracellular phosphate impairs ATP production
• Hypophosphatemia causes rhabdomyolysis and cardiac arrhythmias
• Hypokalemia compounds myocardial irritability
• Hypomagnesemia prevents NMDA antagonism, increasing seizure risk

Patients may present with sudden cardiac events, seizures, or acute kidney injury despite appearing "stable" on labs ordered months prior.

Baseline Labs Before Any GLP-1 Consideration

For patients with eating disorder history requesting GLP-1s:

• Comprehensive metabolic panel: Phosphate, potassium, magnesium, calcium, glucose
• Magnesium RBC (intracellular): Standard serum magnesium misses 99% of total body depletion
• Phosphate levels: Normal range 2.5–4.5 mg/dL; <2.0 indicates severe risk
• Albumin and prealbumin: Assess lean mass reserves
• TSH, free T3, free T4: GLP-1s reduce thyroid hormone absorption and accelerate metabolism
• Cortisol (morning fasting): Eating disorder patients often have dysregulated HPA axis; GLP-1s increase energy expenditure, worsening cortisol stress
• ECG: Baseline QTc and PR intervals essential given arrhythmia risk
• EBV, CMV serology: Eating disorder patients show compromised immune function; GLP-1s increase metabolic stress

Evidence-Based Intervention Framework

1. Screen aggressively: Eating disorder questionnaires (SCOFF, EDE-Q) should be part of GLP-1 screening, not afterthought.

2. Restrict access: GLP-1 prescribing in eating disorder populations should require psychiatry co-management and monthly lab monitoring (phosphate, magnesium, potassium, weight trend).

3. Educate patients on true mechanism: Many patients believe GLP-1s "work" by burning calories. Correct this—they work by suppressing appetite drive, a mechanism that intersects directly with eating disorder cognition.

4. Monitor for dose escalation: Patients often increase doses beyond FDA recommendations. Transparent prescription systems and pharmacy coordination prevent this.

5. Reframe weight loss goals: If a patient with eating disorder history needs metabolic support, consider GLP-1s only after psychiatric clearance and establishment of supervised nutritional rehabilitation.

The Bottom Line

GLP-1 agonists are powerful metabolic tools with legitimate clinical applications in diabetes and obesity. However, their mechanism—profound appetite suppression via hypothalamic GCG-R signaling—aligns perfectly with eating disorder pathology, making them uniquely vulnerable to misuse in this population.

Providers must integrate eating disorder screening into GLP-1 evaluation, establish baseline electrolyte and metabolic status, and maintain high clinical suspicion for dose escalation and compensatory restriction. This is not a contraindication to GLP-1 use in all eating disorder patients—but it demands psychiatric collaboration, monthly monitoring, and frank conversations about the neurochemical mechanisms driving appetite suppression.

The legitimacy of GLP-1 therapy in authorized indications should not obscure the reality that, in eating disorder patients, these compounds can become instruments of harm.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.